Jolanda Howe Sells 902 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 902 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $43,223.84. Following the sale, the senior vice president now directly owns 3,524 shares in the company, valued at $168,870.08. This trade represents a 20.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Stock Up 0.1 %

MIRM stock opened at $48.54 on Wednesday. The stock has a market capitalization of $2.33 billion, a P/E ratio of -24.03 and a beta of 0.98. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $49.58. The firm has a 50-day moving average price of $43.90 and a 200-day moving average price of $41.68.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.57) earnings per share. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on MIRM. Leerink Partners upped their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup upped their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $57.10.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares during the last quarter. Amalgamated Bank raised its holdings in Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after buying an additional 513 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Mirum Pharmaceuticals by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock valued at $421,000 after purchasing an additional 1,003 shares during the period. R Squared Ltd acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at approximately $69,000. Finally, Secure Asset Management LLC increased its position in Mirum Pharmaceuticals by 9.3% during the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock valued at $1,651,000 after purchasing an additional 3,406 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.